Skip to content
MARKETS / NYSE / BDX
NYSE · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · LARGE CAP

Becton Dickinson & Co. BDX

19 fiscal years on record · USD · FY2025 reported · SEC filings only
12 YEARS OF DIVIDEND GROWTH
$21.8B
▲ 8.2% YoY
$1.7B
▼ 1.6% YoY
$2.7B
▼ 14.4% YoY
In brief

What this company does

BD develops, manufactures and sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. As of September 30, 2025, BD had approximately 72,000 associates located in 61 countries. As of September 30, 2025, BD's operations consisted of three worldwide business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical produces medical technologies and devices used across a wide range of healthcare delivery settings. BD Life Sciences provides products for the collection and transport of diagnostic specimens, along with instruments and reagent systems used to detect infectious diseases, healthcare-associated infections and cancers. BD Interventional provides vascular, urology, oncology and surgical specialty products that are intended for single use or for temporary or permanent implantation. Becton, Dickinson and Company was incorporated under the laws of the State of New Jersey in November 1906, as successor to a New York business started in 1897.

Written from the business description in BECTON DICKINSON & CO's annual report to the U.S. Securities and Exchange Commission, filed 25 November 2025. Every sentence was checked against that document before publication.

Growth
USD 21.8B
Revenue, FY2025 · full 19-year series below
Revenue $B Net income $B
FY2025 · Revenue 21.8 · Net income 1.7
8B16B2007201020132016201920222025
Compound annual growth
+5.0%
+6.3%
+7.8%
+7.8%
−1.9%
+13.9%
+9.2%
−0.3%
+16.5%
+5.7%
+0.4%
+6.1%
+5.7%
+5.7%
+7.1%
+11.6%
+16.4%
+16.3%
+5.2%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +6.3% a year over five years — but profit grew faster: net income at +13.9%, earnings per share at +16.5%.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
8 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 11.8% · Net 7.7%
10%20%2007201020132016201920222025
ROE
FY2025 · ROE 6.5%
10%20%2007201020132016201920222025

Each USD of equity produced 7 cents of profit this year.

Cash & shareholders
USD 2.2B
returned in FY2025 · dividends + net buybacks
Free cash flow $B
FY2025 · FCF 2.7
2B2007201020132016201920222025
Net buybacks $B Dividends $B
FY2025 · Dividends 1.2 · Net buybacks 1.0
1B2BDividendsNet buybacks2007201020132016201920222025

USD 1.2B in dividends and USD 1.0B in buybacks — 131% of the year's profit, so the payout drew on cash built up earlier.

Total assetsUSD 55.3B
EquityUSD 25.4B
CashUSD 641.0M
Gross debtUSD 19.2B
Net debtUSD 18.5B
Current ratio1.11×

Net debt stands at 73% of equity.

The 19-year record
19 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013201220112010200920082007
Revenue $B21.820.219.418.919.116.117.316.012.112.510.38.48.17.77.67.17.06.96.3
Operating income $B2.62.42.12.32.20.91.81.51.51.41.11.61.31.61.71.61.61.51.2
EBITDA $B5.04.74.44.54.53.04.03.52.62.52.02.21.82.12.22.12.12.01.6
Income tax $B0.20.30.10.10.10.1−0.10.9−0.10.10.00.30.20.40.40.50.40.40.3
Net income $B1.71.71.51.82.10.91.20.31.11.00.71.21.31.21.31.31.21.10.9
Free cash flow $B2.73.12.11.52.92.22.42.01.81.91.11.21.21.21.11.11.11.00.7
EPS, diluted $5.825.864.945.886.852.713.940.604.604.493.355.996.495.595.625.494.994.463.49
Dividend / sh $4.163.803.643.483.323.163.083.002.922.642.402.181.98··1.481.321.14·
Payout %7165756150117802986258703630312826262527
ROE %6.56.65.87.38.83.95.91.810.713.211.423.528.226.124.824.924.422.8·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Compare

This company against its peers

Provenance
Company facts, as filed
How we verify · 0 failures in 80 reconciliationsAUDITED

Reconciled in 19 of 19 fiscal years. 3 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNYSE
Incorporated inNew Jersey
Fiscal year endsSeptember 30
Data on record since2007

Share this section

Download image